2024-05-13 03:56:51 ET
Summary
- Hologic's women's health business benefited from the pandemic but is now facing headwinds that will end in 2024.
- The company has a strong balance sheet, solid track record, and reasonable valuation, making it an attractive investment.
- Hologic recently made another bolt-on acquisition and expects organic sales to grow by 5-7%, leading to potential valuation expansion.
In February, I believed that shares of Hologic, Inc. ( HOLX ) were starting to look a bit more attractive as headwinds were disappearing. The women's health business benefited greatly from the pandemic (through its diagnostics business) yet the subsequent headwinds are ending in 2024....
Read the full article on Seeking Alpha
For further details see:
Hologic: Women's Health Play Looks Healthier Itself